Get the Stockscreener App
52.64
5.77%
2.87
Spruce Biosciences Inc stock is traded at $52.64, with a volume of 42,209.
It is up +5.77% in the last 24 hours and up +13.55% over the past month.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
See More
Previous Close:
$49.77
Open:
$50.14
24h Volume:
42,209
Relative Volume:
0.67
Market Cap:
$151.29M
Revenue:
$697.00K
Net Income/Loss:
$-37.19M
P/E Ratio:
-1.3965
EPS:
-37.6952
Net Cash Flow:
$-29.34M
1W Performance:
+12.31%
1M Performance:
+13.55%
6M Performance:
-20.59%
1Y Performance:
-90.31%
1-Day Range:
$48.55
$52.64
1-Week Range:
$45.01
$52.64
52-Week Range:
$7.26
$240.00
Spruce Biosciences Inc Stock (SPRB) Company Profile
Name
Spruce Biosciences Inc
Sector
Industry
Phone
(415) 655-4168
Address
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
52.64 | 135.28M | 697.00K | -37.19M | -29.34M | -37.70 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | Craig Hallum | Buy |
| Dec-23-25 | Initiated | Oppenheimer | Outperform |
| Dec-03-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-28-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Dec-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-11-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-14-24 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-14-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-14-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-14-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-21-24 | Initiated | Guggenheim | Buy |
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | The Benchmark Company | Speculative Buy |
| Nov-16-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-19-21 | Initiated | H.C. Wainwright | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-20 | Initiated | SVB Leerink | Outperform |
View All
Spruce Biosciences Inc Stock (SPRB) Latest News
OrbiMed discloses 7.3% ownership of Spruce Biosciences (SPRB) common stock - Stock Titan
Spruce Biosciences (SPRB): ADAR1, Schneeberger disclose 2.5% beneficial stake - Stock Titan
Citadel entities and Kenneth Griffin (SPRB) report 1.9% beneficial stake in Spruce - Stock Titan
Spruce Biosciences (SPRB) sees AWM Investment disclose 5.1% equity stake - Stock Titan
SPRB Maintained by Citizens -- Price Target Lowered to $144 - GuruFocus
Spruce Biosciences (NASDAQ:SPRB) Given New $144.00 Price Target at Citizens Jmp - MarketBeat
Citizens cuts Spruce Biosciences stock price target on share dilution - Investing.com
Citizens cuts Spruce Biosciences stock price target on share dilution By Investing.com - Investing.com Canada
Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - BioSpace
Spruce Biosciences (NASDAQ:SPRB) Issues Quarterly Earnings Results, Misses Estimates By $0.89 EPS - MarketBeat
Spruce Biosciences Q2 Results: EPS Misses Estimate, Losses Widen 91% YoY - scanx.trade
Spruce Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Form 8K Spruce Biosciences Inc For: 12 August By Investing.com - Investing.com South Africa
Spruce Biosciences, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Spruce Biosciences, Inc. (SPRB) Stock Price, News, Quote & History - Yahoo! Finance Canada
SPRUCE BIOSCIENCES, INC. 2Q 2026: Net loss $(16.2M), EPS $(6.68) — 10-Q Summary - TradingView
SPRB: TA-ERT BLA submission and confirmatory study set for Q4 2026, with strong cash reserves and new leadership - TradingView
Spruce Biosciences reports Q2 2026 net loss $16.2M, cash $96.3M; BLA for TA-ERT expected Q4 2026 - TradingView
Spruce Biosciences Q2 2026 Results: Expenses Rise Ahead of the TA-ERT Filing - TradingKey
SPRB: Q2 2026 net loss rose to $16.2M as R&D spending surged, with $96.3M in cash on hand - TradingView
Spruce Biosciences (SPRB) ramps TA-ERT spend while lifting cash to $96.3M - Stock Titan
Spruce Biosciences posts $16.2 million Q2 net loss - Quiver Quantitative
Spruce Biosciences Q2 net loss widens on higher expenses - TradingView
Spruce Biosciences (SPRB) doubles cash as TA-ERT BLA and $5.5M backing advance - Stock Titan
Spruce Biosciences receives $5.5M from patient advocacy groups - Investing.com
Spruce Biosciences receives $5.5M from patient advocacy groups By Investing.com - Investing.com Canada
Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences - Business Wire
Spruce Biosciences, Inc. announced that it has received $5.500192 million in funding - marketscreener.com
SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy - Stocktwits
Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - The National Law Review
Spruce Biosciences, Inc. announced that it expects to receive $5.500192 million in funding - marketscreener.com
Spruce Biosciences (SPRB) to Announce Quarterly Earnings on Thursday - MarketBeat
Spruce Biosciences stock rises on MPS IIIB data, analyst initiation By Investing.com - Investing.com Nigeria
BlackRock, Inc. Adds to Spruce Biosciences Inc (SPRB) Position -- Shares Look 1032% Overvalued on GF Value - GuruFocus
Millennium entities and Israel Englander report 160,981 SPRB shares in joint filing - Stock Titan
Spruce Biosciences names Jessica Cohen Pfeffer as VP of development By Investing.com - Investing.com Nigeria
Spruce Biosciences Appoints Jessica Cohen Pfeffer as Vice President of Clinical Development - citybiz
Spruce Biosciences names Jessica Cohen Pfeffer as VP of development - Investing.com
Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development - Business Wire
Spruce Biosciences (SPRB) Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 4.6%Analyst Earnings Estimate - dars.gov.et
Form 4 Spruce Biosciences Inc For: 30 July By Investing.com - Investing.com Canada
BlackRock, Inc. (SPRB) reports 6.8% beneficial ownership in Spruce Biosciences - Stock Titan
Grant of 13,000 RSUs to Spruce Biosciences (SPRB) Chief Medical Officer - Stock Titan
Spruce Biosciences | 3: Initial statement of beneficial ownership of securities- Quartel Adrian W - Moomoo
Spruce Biosciences Names Adrian Quartel Chief Medical Officer - The Globe and Mail
Spruce Biosciences names Adrian Quartel as CMO - The Pharma Letter
Spruce Biosciences Inc (SPRB) Cash Flow - TradingKey
Spruce Biosciences (SPRB) gains 9.1% shareholder group led by AIGH - Stock Titan
Spruce Biosciences Welcomes Adrian Quartel as Chief Medical Officer - Contract Pharma
Spruce Biosciences, Inc. Files Form 8-K: Company Details, Nasdaq Listing, and Corporate Information (July 2026) - Minichart
Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer - Investing News Network
Spruce Biosciences Inc Stock (SPRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):